Clinical & Translational Insights from the Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel)

Time: 12:30 pm
day: Day Two

Details:

  • Evaluating clinical trial results from phase 1 (CRB-401) and phase 2 (MM-001) trials
  • Reviewing clinical correlates of efficacy and safety to ide-cel
  • Reviewing translational correlates of safety and efficacy to ide-cel

Speakers: